FI104896B - Förfarande för framställning av 1,4,5-trisubstituerad-3-hydroxipyridiniumförening - Google Patents

Förfarande för framställning av 1,4,5-trisubstituerad-3-hydroxipyridiniumförening Download PDF

Info

Publication number
FI104896B
FI104896B FI930367A FI930367A FI104896B FI 104896 B FI104896 B FI 104896B FI 930367 A FI930367 A FI 930367A FI 930367 A FI930367 A FI 930367A FI 104896 B FI104896 B FI 104896B
Authority
FI
Finland
Prior art keywords
formula
compound
group
acid
optionally substituted
Prior art date
Application number
FI930367A
Other languages
English (en)
Finnish (fi)
Other versions
FI930367A (fi
FI930367A0 (fi
Inventor
Laszlo Revesz
Rudolfy Waelchli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of FI930367A0 publication Critical patent/FI930367A0/fi
Publication of FI930367A publication Critical patent/FI930367A/fi
Application granted granted Critical
Publication of FI104896B publication Critical patent/FI104896B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Paper (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Soft Magnetic Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (5)

1. Förfarande för framställning av en 1,4,5-t ri subs t i tuerad- 3 -hydroxipyridiniumförening enligc formel X 5 Rs R1
10 V® Xj Θ 1¾ -fl. 15 väri Rs är -NHj, -NHYa eller NHZa-Yö, väri Y. är en amino skyddande grupp, Z, är succinyl, β-Ala eller en divalent rest, vilken erhälls frän 3-aminopropansyra, 3-aminoisobutansyra, 4-aminobutansyra, NH2-C (CH3) 2-COOH, 20 6-aminohexansyra, 1,8-diaminooktan, 1,6-diaminohexan eller NH,-(CH2) ^-CO-NH-CH, (3.β) -NH, och Yb är en amino skyddande grupp eller en antigengrupp, den amino skyddande gruppen har valts frän bentsoyl, vars fenylring kan vara valbart substituerad med en 25 substituent p-metoxikarbonyl, p-metoxi eller p-nitro; ·1 t-butyloxikarbonyl; isobutyloxikarbonyl; metoxikarbo- nyl; allyloksikarbonyl; 9-fluorenylmetoxikarbonyl; bentsyloxikarbonyl, vars fenylring kan vara valbart substituerad med en substituent p-metoxi, p-nitro, o-30 eller p-klor, m-fenyl eller 3,4-dimetyl; bentsyl, vars ring kan vara valbart substituerad med en substituent p-metoxi, p-nitro eller p-klor; eller fenylsulfonyl, vars ring kan vara valbart substituerad med en substituent p-metyl eller p-metoxi; antigengruppen är vald 35 frän ett nötkreaturs serumalbumin, äggalbumin, tyrog-lobulin eller keyhole limpet hemocyanin, • · « 25 1 0 4 8 9 6 Re är -COOH, C2_7alkoxikarbonyl, CONH2, CONHYa eller -CONH-Za-Yb, väri Ya/ Za och Yb är de samma sorti ovan, är H eller OH och X2~ är en anjon, 5 kännetecknat därav, att en förening enligt formal II, V - väri Rj och Re är de samma som ovan, fär reagera med en 15 förening med formel III, X5 - CH2 - CHXi - CH2 - CH2 - CHRsRe (III) vari
2. X2/ Rs och R6 är de samma som ovan, och Xs är en grupp som spjälks bort; och den sälunda erhällna föreningen enligt formel X tas tillvara i fri form eller i form av ett salt. 25 1 9 >
FI930367A 1992-01-31 1993-01-28 Förfarande för framställning av 1,4,5-trisubstituerad-3-hydroxipyridiniumförening FI104896B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929202139A GB9202139D0 (en) 1992-01-31 1992-01-31 Improvements in or relating to organic compounds
GB9202139 1992-01-31

Publications (3)

Publication Number Publication Date
FI930367A0 FI930367A0 (fi) 1993-01-28
FI930367A FI930367A (fi) 1993-08-01
FI104896B true FI104896B (sv) 2000-04-28

Family

ID=10709643

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930367A FI104896B (sv) 1992-01-31 1993-01-28 Förfarande för framställning av 1,4,5-trisubstituerad-3-hydroxipyridiniumförening

Country Status (16)

Country Link
EP (1) EP0556152B1 (sv)
JP (1) JP3544549B2 (sv)
AT (1) ATE210645T1 (sv)
AU (1) AU663909B2 (sv)
CA (1) CA2088396A1 (sv)
CZ (1) CZ288038B6 (sv)
DE (1) DE69331293T2 (sv)
DK (1) DK0556152T3 (sv)
ES (1) ES2169723T3 (sv)
FI (1) FI104896B (sv)
GB (1) GB9202139D0 (sv)
HU (1) HU214677B (sv)
NO (1) NO180779C (sv)
PT (1) PT556152E (sv)
SG (1) SG43065A1 (sv)
SK (1) SK281137B6 (sv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620861A (en) * 1992-07-31 1997-04-15 Metra Biosystems, Inc. Method and kit for pyridinium crosslink assay
US5736344A (en) * 1992-12-17 1998-04-07 Metra Biosystems, Inc. Serum pyridinium crosslinks assay
US5756361A (en) * 1992-12-17 1998-05-26 Metra Biosystems, Inc. Screening method for periodontal disease
US5661039A (en) * 1995-03-01 1997-08-26 Metra Biosystems, Inc. Perspiration assay for bone resorption
US5723619A (en) * 1997-01-13 1998-03-03 Bayer Corporation Method for the synthesis of deoxypyridinoline
US5834610A (en) * 1997-05-06 1998-11-10 Johnson; Gary M. Conversion of pyridinoline to deoxypyridinoline
CN105801688A (zh) * 2016-04-14 2016-07-27 苏州博源医疗科技有限公司 脱氧吡啶酚免疫原、抗体和检测试剂及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59148766A (ja) * 1983-02-10 1984-08-25 Otsuka Pharmaceut Co Ltd ピリジン誘導体
US4973666A (en) * 1987-11-06 1990-11-27 Washington Research Foundation Peptide fragments containing HP and LP cross-links
GB8929366D0 (en) * 1989-12-30 1990-02-28 Rowett Research Inst Method to detect connective tissue disorder in humans and animals

Also Published As

Publication number Publication date
ES2169723T3 (es) 2002-07-16
DK0556152T3 (da) 2002-04-08
AU663909B2 (en) 1995-10-26
SK281137B6 (sk) 2000-12-11
FI930367A (fi) 1993-08-01
DE69331293D1 (de) 2002-01-24
CZ288038B6 (cs) 2001-04-11
JPH0641078A (ja) 1994-02-15
CZ10693A3 (en) 1993-12-15
SG43065A1 (en) 1997-10-17
JP3544549B2 (ja) 2004-07-21
CA2088396A1 (en) 1993-08-01
SK4293A3 (en) 1993-11-10
FI930367A0 (fi) 1993-01-28
NO180779B (no) 1997-03-10
DE69331293T2 (de) 2002-07-18
EP0556152B1 (en) 2001-12-12
EP0556152A1 (en) 1993-08-18
HU214677B (hu) 1998-04-28
NO930284L (no) 1993-08-02
NO930284D0 (no) 1993-01-28
HUT70276A (en) 1995-09-28
GB9202139D0 (en) 1992-03-18
NO180779C (no) 1997-06-18
ATE210645T1 (de) 2001-12-15
AU3210593A (en) 1993-08-05
HU9300108D0 (en) 1993-04-28
PT556152E (pt) 2002-05-31

Similar Documents

Publication Publication Date Title
JP3327551B2 (ja) 流体試料中のチロキシンを検出・定量するための試薬および方法
Song et al. Practical synthesis of maleimides and coumarin-linked probes for protein and antibody labelling via reduction of native disulfides
AU2010284614B2 (en) Imatinib immunoassay
JP2015096549A (ja) リスペリドンイムノアッセイ
AU2011224719A1 (en) Lenalidomide and thalidomide immunoassays
AU2013305904A1 (en) Antibodies to quetiapine haptens and use thereof
AU2013305895A1 (en) Antibodies to olanzapine haptens and use thereof
CN104854110A (zh) 奥氮平半抗原
JP2016510413A (ja) 分子の検出のための光又は化学解離性コンジュゲート
AU2013305935A1 (en) Haptens of quetiapine for use in immunoassays
CA2586511A1 (en) Immunoassays for lamotrigine
US8846411B2 (en) Derivatives, reagents, and immunoassay for detecting levetiracetam
FI104896B (sv) Förfarande för framställning av 1,4,5-trisubstituerad-3-hydroxipyridiniumförening
WO2008145609A1 (en) Method of making covalent conjugates with his-tagged proteins
US6140137A (en) Conjugates and specific immunoassays for the methadone metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine
KR100259761B1 (ko) 에스에이치기 표지용시약, 그의 제조방법 및 이를 이용한 표지법
CA2216880A1 (en) Reagents and methods for the detection and quantification of vancomycin in biological fluids
Adamczyk et al. Synthesis of immunocomponents for the measurement of lead (Pb) by fluorescence polarization immunoassay
US6175016B1 (en) Pyridine derivatives
US5824786A (en) Synthesis of galactosylhydroxylysine
JPH09249662A (ja) アクリジン誘導体、その製法およびこれを用いた標識法
Bailey et al. Strategies For Increasing The Sensitivity of N-Terminal Sequence Analysis
EP0265496A1 (en) Flecainide derivatives and their use in immunoassays.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG